Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 13.4% during the 4th quarter, Holdings Channel reports. The firm owned 703,867 shares of the biopharmaceutical company’s stock after selling 108,494 shares during the period. Peregrine Capital Management LLC’s holdings in Amicus Therapeutics were worth $8,594,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Duality Advisers LP acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $1,927,000. ProShare Advisors LLC lifted its position in shares of Amicus Therapeutics by 2.3% during the third quarter. ProShare Advisors LLC now owns 53,997 shares of the biopharmaceutical company’s stock worth $563,000 after purchasing an additional 1,211 shares in the last quarter. Assetmark Inc. lifted its position in shares of Amicus Therapeutics by 71.0% during the third quarter. Assetmark Inc. now owns 20,570 shares of the biopharmaceutical company’s stock worth $215,000 after purchasing an additional 8,543 shares in the last quarter. SevenOneSeven Capital Management acquired a new stake in Amicus Therapeutics in the third quarter valued at approximately $309,000. Finally, PDT Partners LLC acquired a new stake in Amicus Therapeutics in the third quarter valued at approximately $318,000.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $11.24 on Friday. Amicus Therapeutics, Inc. has a 52 week low of $5.91 and a 52 week high of $13.84. The company has a current ratio of 3.05, a quick ratio of 2.88 and a debt-to-equity ratio of 3.19. The firm’s 50 day moving average is $12.62 and its two-hundred day moving average is $11.69.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on FOLD. BTIG Research raised their target price on shares of Amicus Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, January 18th. UBS Group raised their target price on shares of Amicus Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, March 2nd. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday. Finally, The Goldman Sachs Group raised their target price on shares of Amicus Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, March 2nd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $14.75.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, insider David Michael Clark sold 8,493 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $12.03, for a total value of $102,170.79. Following the transaction, the insider now directly owns 190,203 shares in the company, valued at $2,288,142.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Chairman John F. Crowley sold 6,044 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $11.34, for a total transaction of $68,538.96. Following the transaction, the chairman now directly owns 986,537 shares in the company, valued at $11,187,329.58. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Michael Clark sold 8,493 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $12.03, for a total transaction of $102,170.79. Following the transaction, the insider now owns 190,203 shares in the company, valued at $2,288,142.09. The disclosure for this sale can be found here. Insiders have sold 365,427 shares of company stock worth $4,583,219 over the last three months. Insiders own 2.40% of the company’s stock.

Amicus Therapeutics Profile

(Get Rating)

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.